Management of comorbidities in haemophilia
- PMID: 32476243
- DOI: 10.1111/hae.14013
Management of comorbidities in haemophilia
Abstract
With the introduction of clotting factor concentrates in the early 1970s, significant improvements in quality of life and life expectancy of persons with haemophilia (PWH) were realized. Unfortunately, as a result of transmission of HIV and hepatitis C virus (HCV) by contaminated concentrates in the 1980s, many of these gains were lost. Now with four decades of PWH unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, the survival rate is once again increasing. In addition to the usual comorbidities associated with advanced age in the general population, several specific issues occur in patients with bleeding disorders. This manuscript explores the incidence and management of the comorbidities of the ageing PWH with a focus on cardiovascular disease and osteoporosis.
Keywords: ageing; cardiovascular diseases; haemophilia; osteoporosis.
© 2020 John Wiley & Sons Ltd.
References
REFERENCES
-
- Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815-825.
-
- Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol. 2019;184:712-720.
-
- Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100-1112.
-
- Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol. 1996;94:746-752.
-
- Fransen van de Putte DE, Makris M, Fischer K, et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol. 2014;60:39-45.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
